Premium
Hydroxyurea use during pregnancy: A case report in sickle cell disease and review of the literature
Author(s) -
DiavCitrin Orna,
Hunnisett Laura,
Sher Graham D.,
Koren Gideon
Publication year - 1999
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199902)60:2<148::aid-ajh12>3.0.co;2-i
Subject(s) - pregnancy , medicine , disease , hemoglobinopathy , medline , pediatrics , obstetrics , intensive care medicine , genetics , biology , biochemistry
A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age. The pregnancy and delivery were complicated by vaso‐oclusive crises. A healthy male infant was born at 39 weeks with no evidence of congenital malformations. A literature review, including this case, suggests that the risk of hydroxyurea exposure during in pregnancy may have been overestimated. Further studies are required to determine its safety in pregnancy. Am. J. Hematol. 60:148–150, 1999. © 1999 Wiley‐Liss, Inc.